Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report ...

The board of Gilead Sciences, Inc. (NASDAQ:GILD) has announced that it will be paying its dividend of $0.79 on the 28th of March, an increased payment from last year's comparable dividend.

NASDAQ GILD opened at $109.95 on Friday. The business has a 50 day simple moving average of $95.41 and a 200 day simple moving average of $88.63. Gilead Sciences has a 52-week low of $62.07 and a ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, and downgraded Merck (NYSE:MRK), citing the cancer drugmaker’s ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Gilead Sciences Inc. and Johnson & Johnson’s Janssen unit settled lawsuits with Apotex Inc. over its proposed generic versions of HIV treatments Symtuza and Genvoya and with Lupin Ltd. and its ...

Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Have you been paying attention to shares of Gilead Sciences (GILD)? Shares have been on the move with the stock up 13.3% over the past month. The stock hit a new 52-week high of $106.69 in the ...